Evidence map›Paper›PMID 29130325›Full record

Trial reportClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis2018

The Plasma Levels of ADAMTS-13, von Willebrand Factor, VWFpp, and Fibrin-Related Markers in Patients With Systemic Sclerosis Having Thrombosis.

Koji Habe, Hideo Wada, Ayaka Higashiyama, Tomoko Akeda, Kenshiro Tsuda, Ryoko Mori, Masato Kakeda, Takeshi Matsumoto, Kohshi Ohishi, Keiichi Yamanaka and 2 more

Open access · hybridAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Koji Habe1 Department of Dermatology, Mie University Graduate School of Medicine, Mie, Tsu, Japan.
Hideo Wada2 Department of Molecular and Laboratory Medicine, Mie University Graduate School of Medicine, Mie, Tsu, Japan.
Ayaka Higashiyama1 Department of Dermatology, Mie University Graduate School of Medicine, Mie, Tsu, Japan.
Tomoko Akeda1 Department of Dermatology, Mie University Graduate School of Medicine, Mie, Tsu, Japan.
Kenshiro Tsuda1 Department of Dermatology, Mie University Graduate School of Medicine, Mie, Tsu, Japan.
Ryoko Mori1 Department of Dermatology, Mie University Graduate School of Medicine, Mie, Tsu, Japan.
Masato Kakeda1 Department of Dermatology, Mie University Graduate School of Medicine, Mie, Tsu, Japan.
Takeshi Matsumoto3 Department of Blood Transfusion, Mie University Graduate School of Medicine, Mie, Tsu, Japan.
Kohshi Ohishi3 Department of Blood Transfusion, Mie University Graduate School of Medicine, Mie, Tsu, Japan.
Keiichi Yamanaka1 Department of Dermatology, Mie University Graduate School of Medicine, Mie, Tsu, Japan.
Naoyuki Katayama4 Department of Hematology and Oncology, Mie University Graduate School of Medicine, Tsu, Japan.
Hitoshi Mizutani1 Department of Dermatology, Mie University Graduate School of Medicine, Mie, Tsu, Japan.
Mie University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to examine the hemostatic abnormalities in patients with systemic sclerosis (SSc) and the relationship between these abnormalities and thrombotic events (THEs), focusing on the difference in diffuse cutaneous SSc (dcSSc) and limited cutaneous SSc (lcSSc). The plasma levels of ADAMTS-13 (a disintegrin-like and metalloproteinase with thrombospondin type 1 motifs 13), von Willebrand factor (VWF), VWF propeptide (VWFpp), d-dimer, and soluble fibrin (SF) were measured in 233 patients with SSc. The relationship between their levels and organ involvement, including THEs and interstitial lung disease (ILD), was evaluated. The plasma levels of VWF and VWFpp were significantly elevated and ADAMTS-13 activity was significantly decreased in patients with SSc compared to healthy participants. The VWFpp in dcSSc was significantly higher than in lcSSc. Twelve patients with SSc were complicated with acute THE, and 25 patients with SSc were complicated with past THE. The plasma levels of d-dimer and SF were significantly elevated in patients with SSc having THE. The plasma levels of VWF and VWFpp were significantly elevated in patients with SSc having ILD. The plasma levels of d-dimer were elevated in patients with SSc having other connective tissue diseases (CTDs). The plasma levels of ADAMTS-13 were significantly decreased and VWF, VWFpp, and SF were increased in patients with a d-dimer level of ≥1 μg/mL. Systemic sclerosis carries a high risk of THE, especially in patients with other CTDs. Plasma hemostasis-related markers are closely related to ILD and THE. These markers are important as markers of organ involvement as well as THE.

Indexed as

Scleroderma, SystemicThrombosisAcute DiseaseADAMTS13 ProteinAgedBiomarkersFemaleFibrin Fibrinogen Degradation ProductsHumansMaleMiddle Agedvon Willebrand FactorADAMTS13 ProteinADAMTS13 protein, humanBiomarkersFibrin Fibrinogen Degradation Productsfibrin fragment Dvon Willebrand FactorADAMTS-13d-dimersoluble fibrinsystemic sclerosisVWFVWFpp

Identifiers

PMID29130325
PMCPMC6714713
OpenAlexW2767668635

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.